Results of the five-year clinical trial MINDACT – presented today at the AACR’s Annual Meeting – have suggested that the MammaPrint genetic test could help identify a group of early-stage breast cancer patients that might not need chemotherapy after surgery to prevent future recurrence.
Among the 3,356 patients with early-stage breast cancer on the trial who were considered at high risk for disease recurrence based on clinical and biological criteria, the 70-gene MammaPrint test identified a large group of patients for whom five-year distant metastasis–free survival was equally good (94.7%) whether or not they received chemotherapy post-surgery.
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
“This is very promising news. If proven effective, this gene test could identify women that will gain no benefit from chemotherapy, so sparing them the gruelling side-effects.
“By the same token, the test could also more accurately identify patients for whom chemotherapy will help reduce the risk of their breast cancer spreading.
“It’s so important that we find ways to ensure patients receive the treatments most appropriate for them. We look forward to further results from this and other trials in the future.”